Precision Life Sciences offers an intelligent, molecular diagnostic solution. This is a unique, data-driven approach that combines precise, molecular pathogen and resistance gene detection with regional sensitivity and susceptibility data. Our report supports clinicians in providing the most targeted and customized treatment plan for their patients.
Precision Life Sciences offers one of the most extensive Resistance Gene Testing Panel on the market today, identifying 30 resistance genes that could lead to ineffective antibiotic therapy, including the genes for the enzymes associated with ESBL, which can have even worse outcomes than MRSA.
Traditional culture technique involves using special mediums in a microbiology lab to try to grow potential pathogens. Precision Life Sciences is a molecular lab and we do not grow pathogens. Instead, we utilize short segments of DNA and RNA sequences (primers) to specifically and accurately identify the same sequences within the patient’s sample. We have developed customized pathogen panels per type of body system being evaluated. We test the majority of the pathogens in the U.S. associated with infections of each of the systems being targeted.
Although culture has been the “gold standard” for many years and helped us identify and treat billions of patients, it is becoming more difficult for today’s pathogens to grow in these culture mediums. This technique was originally developed to grow “planktonic” cells in an artificial medium developed outside of the body (in vitro) to resemble the preferred environment of the pathogen inside of the body (in vivo). These planktonic cells have the cell wall that can adhere to these mediums. However, the cells being identified in the majority of infections today are felt to originate from “Biofilms” and vary phenotypically from the planktonic cells by as much as 70%. They do not contain the cell walls of planktonic cells and therefore do not readily attach to the culture mediums and can’t be grown.
Biofilms are communities of microorganisms that are encased in a slimy matrix of polysaccharides, proteins and DNA. The protective covering of the biofilm can adhere to surfaces but the individual cells within the matrix cannot survive in their current state outside of the biofilm. If they are dispersed from the biofilm, they begin a transformation of up-regulating specific genes for survival outside of their environment.
Even though these microorganisms within the biofilm are felt to be the same genotypically, they have the ability to turn ON (up-regulate) and OFF (down-regulate) particular genes based off their need to utilize them. These microorganisms can communicate through cell signaling and carry out different functions than the freestanding planktonic cells outside of the biofilm. They are stronger together and can also fight differently against our human host defenses and antibiotic therapies. In fact, our current antibiotic therapies were developed to kill planktonic cells so the mechanism of action of the antibiotic(s) may not be suitable to kill these biofilm cells, despite the presence or absence of resistance genes.
The sample collection method for PCR testing is much easier than for culture due to the lack of limiting factors like volume/size of the sample, temperature, time or concomitant medication usage.
PLS needs the equivalent of 1 mg or 1 mL of the patient’s specimen being sampled. This enables all testing to be collected by the swab method. We are analyzing RNA/DNA and do not need a large sample size. We are also not trying to keep the pathogen alive to grow it so the strict specifications of time and temperature do not apply for the purpose of detection.
Conventional culture can take an average of 3 to 7 days to grow pathogens. Because providers are not comfortable waiting this long to treat patients, they have had no other option but to guess at the possible culprit pathogen and treat the patient empirically with broad-spectrum antibiotics. These practices have led to treatments that are ineffective or inappropriate, excess pharmacy costs, complications such as adverse drug events, extended hospital stays and the progression of disease. We are now experiencing and epidemic of antibiotic resistance that is affecting us globally. We are running out of antibiotics and urgently looking for other types of therapies to prevent a reverse of the medical advancements for infectious disease.
The Turn-Around-Time for molecular pathogen testing is 24 hours from the time the sample arrives at PLS. There could be delays due to a lack of a provider signature, missing information or the need to rerun a particular test but this is not often.
Given we are not growing the pathogen(s) in a medium and introducing the pathogen(s) to specific antibiotics, we offer OneChoice as an adjunct to traditional molecular pathogen testing. Precision’s utilization of the OneChoice reporting technology integrates the patient’s specific molecular test results with regional sensitivity and susceptibility data that is updated DAILY by the most trusted resource in the treatment of infectious disease, the Sanford Guide.
Even though we now understand the barriers for pathogen growth in a culture medium, let’s assume it does grow. The next step in the microbiology lab would be to perform susceptibility testing (expose the growth to different antibiotics). This is a single in vitro study of the pathogen that does not take into consideration: the effect of human host responses such as pharmacokinetics or pharmacodynamics, the variability of concentration needed at the site of infection, toxin production by bacteria, the presence of resistance genes that could be activated at any time, or the presence of biofilm production. The sensitivity and susceptibility testing we have used over the last century was developed to be a tool for guidance only and without consideration of these variables.
If another option develops aside from growing the pathogen in a medium to test in vitro efficacy of an antibiotic to eradicate the pathogen, it is still in vitro and does not take into consideration all of the things that make us human and dynamic – listed above.
Rapid antigen tests like the Flu have created a false sense of security among patients and providers. When it results “negative” and is wrong, this leads to delayed treatment and poor clinical outcomes. It may lack sensitivity and only focuses on a single pathogen diagnosis. There is a high rate of co-infection in respiratory illness and it is necessary to test all pathogens that could be key culprits for respiratory infections, along with the potential antibiotic resistance.
Biofilm development in these specimens has made it difficult to identify the culprit pathogen(s). Recurrent or persistent UTIs are most likely infections originating from the biofilm. PCR identification is not limited by the presence of biofilm. Development of MDROs in these specimens has made antibiotic resistance testing a necessity.
75% of STIs are asymptomatic. This is why screening has been encouraged. Viruses are treatable but not curable. They can remain in the body for many years and titers can rise and fall based off of good or bad stress on the body. For example, an upper respiratory infection could exacerbate the virus as well as sexual intercourse. The stress does not have to be bad stress on the immune system. It is important to realize the identification of a virus does not mean it was recent. Bacterial infections are treatable and curable.
These are very complicated infections and multi-factorial (infection, inflammation, circulation components). A low percentage of wound pathogens routinely grow in cultures. It is important to rule out infection before considering advanced therapies.
Fortunately, both Federal and Commercial providers see the value of molecular pathogen testing. Medicare, Medicaid, Tricare and most commercial plans cover our testing. If a patient has commercial insurance and has not met their deductible, we are obligated by our agreements with insurance providers to follow the terms of their agreements and invoice patients. We are not partnered with a collections agency and will work closely with patients to construct a payment plan that fits within their budget. We also have a Financial Hardship Program for patients who cannot afford medical care.
Precision Life Science’s results can be accessed electronically through a HIPAA compliant web portal or by fax. We prefer to send via both modalities. We are also able to integrate with most EHR systems within 24-48hrs. We value time and try to make retrieving results convenient so providers can focus on treatment.